MedTrace Logo

Trial of Cannabis for Essential Tremor

NCT03805750 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2022-10-13

Study results available
· View outcomes & findings →

Summary

This is a pilot trial to evaluate the safety and efficacy of a combined oral formulation of THC and CBD in patients with Essential Tremor.

Conditions

Interventions

DRUG

CBD/THC

Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).

DRUG

Placebo oral capsule

Matched Placebo

Sponsors & Collaborators

  • International Essential Tremor Foundation

    collaborator OTHER

  • Tilray

    collaborator INDUSTRY

  • Center for Medicinal Cannabis Research

    collaborator OTHER

  • University of California, San Diego

    lead OTHER

Principal Investigators

  • Fatta Nahab, MD · UCSD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-22
Primary Completion
2020-09-01
Completion
2020-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03805750 on ClinicalTrials.gov